# Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

> **NCT03372083** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Iron Overload

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT03372083
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-16
- **Primary completion:** 2019-12-05
- **Final completion:** 2019-12-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03372083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03372083, "Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03372083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*